Boston Partners Purchases 16,320 Shares of Novartis AG (NYSE:NVS)

Boston Partners boosted its position in Novartis AG (NYSE:NVS - Free Report) by 44.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,359 shares of the company's stock after purchasing an additional 16,320 shares during the quarter. Boston Partners' holdings in Novartis were worth $5,195,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Legacy Investment Solutions LLC purchased a new stake in shares of Novartis in the third quarter worth $28,000. Human Investing LLC bought a new position in Novartis in the 4th quarter worth about $25,000. Union Bancaire Privee UBP SA purchased a new stake in shares of Novartis in the 4th quarter valued at about $27,000. Kestra Investment Management LLC bought a new stake in Novartis during the fourth quarter valued at approximately $47,000. Finally, Clearstead Trust LLC purchased a new position in Novartis in the 4th quarter worth approximately $51,000. 13.12% of the stock is owned by institutional investors.

Novartis Trading Down 0.3 %

Shares of NVS stock traded down $0.30 during mid-day trading on Wednesday, reaching $110.08. The stock had a trading volume of 1,903,973 shares, compared to its average volume of 2,228,338. The firm has a market capitalization of $225.00 billion, a PE ratio of 18.72, a price-to-earnings-growth ratio of 1.70 and a beta of 0.53. The stock's 50-day moving average price is $107.12 and its two-hundred day moving average price is $107.24. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92.

Remove Ads

Novartis (NYSE:NVS - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were issued a $3.8695 dividend. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is currently 42.69%.

Wall Street Analyst Weigh In

NVS has been the topic of several research reports. Morgan Stanley started coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an "underweight" rating on the stock. HSBC lowered Novartis from a "hold" rating to a "reduce" rating in a research note on Wednesday, December 4th. StockNews.com upgraded Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Deutsche Bank Aktiengesellschaft upgraded Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. Finally, Barclays reiterated an "underweight" rating on shares of Novartis in a research report on Monday, February 3rd. Three research analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.